Key Takeaways BlueRock posted 36-month data showing bemdaneprocel remains well tolerated in Parkinson's patientsF-Dopa imaging suggests that transplanted cells survived and engrafted after immunosuppression ended. High-dose patients saw a 17.9-point MDS-UPDRS motor score drop, showing clinically meaningful progress.Bayer AG’s (BAYRY) wholly owned, independently operated subsidiary BlueRock Therapeutics LP announced positive 36-month data from an early-stage study of bemdaneprocel, an investigational cell th ...